This article was originally published in The Gray Sheet
Executive SummaryAnnounce plans to develop jointly a "new vascular access product" to be manufactured by MedAmicus and marketed by Medtronic. MedAmicus estimates that sales under the deal, which are expected to begin in the fourth quarter of 1993, will generate over $1 mil. in annual revenues for the company. Medtronic also markets MedAmicus' vessel introducer.
You may also be interested in...
The Belgian authorities are taking steps to reduce the consumption of benzodiazepine-containing medicines, and have also reiterated the risks associated with the increasing use of opioid medications.
Following closely on the heels of a medical device tax repeal win, AdvaMed CEO Scott Whitaker sat down to discuss how the industry advocacy group ended the Obamacare excise tax and what it has in store for 2020.
“Growth gaps” were the driver for a record-breaking M&A year – but CEOs must remain disciplined when pursuing opportunities, or pay the price down the line.